OncoMatch

OncoMatch/Clinical Trials/NCT06769490

Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

Is NCT06769490 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Ziftomenib and Quizartinib for acute myeloid leukemia.

Phase 1RecruitingM.D. Anderson Cancer CenterNCT06769490Data as of May 2026

Treatment: Ziftomenib · QuizartinibThe goal of this all-oral combination is to deliver safe and effective therapy for the largest portion of AML subtypes (NPM1mt, KMT2Ar, NUP98r \~ 40-45%).

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Biomarker criteria

Required: KMT2A (MLL) rearrangement

Required: NPM1 mutation

Required: NUP98 rearrangement

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Cannot have received: menin inhibitor

Prior treatment with a menin inhibitor

Lab requirements

Kidney function

estimated glomerular filtration rate > 50 mL/min (using Cockcroft-Gault) unless related to disease

Liver function

total bilirubin < 2x ULN unless increase is due leukemic involvement (<2.5 ULN), unless due to ongoing hemolysis or Gilbert's syndrome and AST and/or ALT < 3x ULN unless considered due to leukemic involvement, in which case direct bilirubin or AST and/or ALT < 5x ULN will be considered eligible

Cardiac function

Baseline ejection fraction must be > 40%

Adequate hepatic function (total bilirubin < 2x upper limit of normal (ULN) unless increase is due leukemic involvement (<2.5 ULN), unless due to ongoing hemolysis or Gilbert's syndrome and AST and/or ALT < 3x ULN unless considered due to leukemic involvement, in which case direct bilirubin or AST and/or ALT < 5x ULN will be considered eligible). Adequate renal function with an estimated glomerular filtration rate > 50 mL/min (using Cockcroft-Gault) unless related to disease. Baseline ejection fraction must be > 40%.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • The University of Texas M. D. Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify